- Conditions
- Leukemia, Acute Lymphoblastic, Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 5,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- GEN3017
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Duarte, California • St Louis, Missouri • Houston, Texas
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Interventions
- belinostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 123
- States / cities
- Mobile, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
- Conditions
- Advanced Solid Tumors, Lymphoma
- Interventions
- EZN-2208
- Drug
- Lead sponsor
- Enzon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Stanford, California • Atlanta, Georgia + 8 more
- Conditions
- Multiple Myeloma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Interventions
- Administration of hyperbaric oxygen
- Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
- Interventions
- brentuximab vedotin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 8
- States / cities
- Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, etoposide, prednisone, doxorubicin, cyclophosphamide, Dacarbazine(R), filgrastim, quality of life assessment, radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Peoria, Illinois • Scarborough, Maine + 2 more
- Conditions
- Covid19
- Interventions
- Amended LLS COVID-19 Registry
- Biological
- Lead sponsor
- Blood Cancer United
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,000 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rye Brook, New York
- Conditions
- Lymphoma
- Interventions
- Biaxin (clarithromycin)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Leukemia
- Interventions
- ARA-C, BCNU, Campath-1H, Cyclophosphamide, Etoposide, Fludarabine, Melphalan, Rituximab, Allogeneic Stem Cell Transplantation, Total body radiation (TBI), Methotrexate, Tacrolimus, Adback NK or T Cell
- Drug · Other · Radiation + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- T Cell Lymphoma, T-cell Lymphoma
- Interventions
- Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • New York, New York
- Conditions
- Leukemia
- Interventions
- OPB 31121
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
- Interventions
- Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product
- Radiation · Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
- Biological · Drug · Other
- Lead sponsor
- Jennifer Woyach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Unspecified Childhood Solid Tumor, Protocol Specific, Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- pharmacological study, laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 16 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 31 more
- Conditions
- AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Mantle Cell Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Not listed
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 8 Years to 28 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
- Interventions
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lymphoma
- Interventions
- filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Not listed
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 68
- States / cities
- Tuscaloosa, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 54 more
- Conditions
- Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
- Interventions
- dental intervention
- Procedure
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- AUTO3
- Biological
- Lead sponsor
- Autolus Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Duarte, California • Denver, Colorado • Miami, Florida + 4 more